Literature DB >> 11711899

The value of immunoscintigraphy in the detection of recurrent colorectal cancer.

F Baulieu1, P Bourlier, B Scotto, C Mor, V Eder, L Picon, L De Calan, E Dorval, J M Pottier, J L Baulieu.   

Abstract

The aim of this prospective study was to determine whether anti-carcinoembryonic antigen (anti-CEA) scintigraphy is a useful additional technique in the diagnosis recurrence of colorectal cancer. Forty patients with suspected recurrence of colorectal cancer, underwent immunoscintigraphy (IS) and helical computed tomography (CT) in the 2 weeks before surgery. Surgical findings were used to evaluate the performance of the imaging techniques. Suspected areas on IS and CT were systematically explored. Helical CT was found to be superior to IS for the liver, the sensitivity and specificity of CT being 100% and 90%, respectively, vs 53% and 100% for IS. However, IS was better than CT for the detection of extra-hepatic abdominal recurrence: sensitivity and specificity of IS were 100 and 82% respectively vs 33 and 82% for CT. Seven cases of peritoneal carcinomatosis were overlooked by helical CT. Our results indicate that IS improves detection of extra-hepatic abdominal recurrence of colorectal cancer. Immunoscintigraphy is valuable as a guide to the treatment strategy and operative procedures.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711899     DOI: 10.1097/00006231-200112000-00004

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  2 in total

1.  Immunoscintigraphy of local recurrent rectal cancer with 99mTc-labeled anti-CEA monoclonal antibody CL58.

Authors:  Yun-Feng Yao; Zhi Yang; Zhen-Fu Li; Jin Gu
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

2.  Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen - a prospective study.

Authors:  S Bhattacharjya; R Aggarwal; B R Davidson
Journal:  Br J Cancer       Date:  2006-07-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.